KTTA - Pasithea Therapeutics Corp.
NASDAQ
->
Healthcare
->
Biotechnology
Miami Beach,
United States
Type: Equity
KTTA price evolution
KTTA
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $0.04 | $0.04 | ||
| Inventory | ||||
| Total current assets | $9.78 | $8.64 | $13.19 | $16.69 |
| Long term investments | ||||
| Property, plant & equipment | $0.13 | $0.13 | $0.17 | $0.22 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $18.64 | $17.66 | $22.41 | $26.12 |
| Current liabilities | ||||
| Accounts payable | $0.66 | $1.39 | $2.43 | $2.55 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $0.66 | $1.39 | $2.47 | $2.63 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $0.82 | $1.49 | $2.52 | $2.72 |
| Shareholders' equity | ||||
| Retained earnings | -$46.41 | -$43.05 | -$39.18 | -$35.32 |
| Other shareholder equity | -$0.04 | -$0.01 | -$0.01 | -$0 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $33.15 | |||
| Short term investments | ||||
| Net receivables | $0.04 | $0.3 | ||
| Inventory | ||||
| Total current assets | $16.69 | $34.08 | $53.3 | $0.25 |
| Long term investments | ||||
| Property, plant & equipment | $0.22 | $1.25 | $0.02 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $26.12 | $45.18 | $53.32 | $0.25 |
| Current liabilities | ||||
| Accounts payable | $2.55 | $1.61 | $0.45 | $0.01 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $2.63 | $1.88 | $0.45 | $0.01 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $2.72 | $2.68 | $1.9 | $0.01 |
| Shareholders' equity | ||||
| Retained earnings | -$35.32 | -$19.36 | -$2.21 | -$0.04 |
| Other shareholder equity | -$0 | -$0 | -$0.01 | |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $3 | $3.95 | $4.04 | $5.15 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.08 | $0.11 | $0.15 | $0.17 |
| Net income | ||||
| Net income | -$3 | -$3.87 | -$3.86 | -$5.05 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.02 | |||
| Cost of revenue | ||||
| Gross Profit | $0.37 | |||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $15.98 | $12.59 | $4.5 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.42 | $2.33 | ||
| Net income | ||||
| Net income | -$15.96 | -$13.94 | -$2.17 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $0.4 | |||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $4.54 | -$3.73 | ||
| Effect of exchange rate | -$0.03 | -$0 | -$0 | -$0 |
| Change in cash and equivalents | -$6.97 | -$8.36 | -$4.32 | -$16.76 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $0.4 | -$2.93 | -$0.02 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$3.73 | -$3.21 | $55.93 | |
| Effect of exchange rate | -$0 | $0.01 | -$0.01 | |
| Change in cash and equivalents | -$16.76 | -$19.81 | $52.73 | |
News
Fundamentals
| Market cap | $852.65K |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 1.04M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$15.78M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.05 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$15.10 |
|---|---|
| ROA | -74.39% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 14.81 |
| Quick ratio | N/A |